In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CymaBay Therapeutics Inc.

www.cymabay.com

Latest From CymaBay Therapeutics Inc.

Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation

CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

Biotech thinks its PPAR delta agonist will prove much more potent than Genfit’s elafibranor from the same class and will offer a better tolerability profile than Intercept’s OCA.

Liver & Hepatic Business Strategies

Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets

The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.

Companies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Metabolex Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CymaBay Therapeutics Inc.
  • Senior Management
  • Sujal Shah, Pres. & CEO
    Pol Boudes, MD, CMO
    Patrick J O'Mara, VP, Bus. Dev.
    Charles A McWherter, PhD, SVP, CSO
    Dan Menold, VP, Fin.
  • Contact Info
  • CymaBay Therapeutics Inc.
    Phone: (510) 293-8800
    7575 Gateway Blvd., Ste. 110
    Newark, CA 94560
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register